ViroStat has developed and released a set of new monoclonal antibodies to the nucleocapsid of the COVID-19 virus. These final five antibodies were selected from an initial group of 60 based upon highest binding affinity and best ELISA pairing for detection of native viral antigen.

ViroStat believe the nucleocapsid of COVID-19 virus is ideal for antigen detection for these reasons:

• it is a highly conserved protein and therefore not prone to mutation.
• It is produced abundantly in the cytoplasm of infected cells
• These cells can be collected on a nasopharyngeal swab and added to a specimen buffer to lyse and release this antigen for detection by immunoassay.

The set includes Ig class antibodies: IgG2b, IgG1 and IgG. These are specific for the nucleoprotein of COVID-19 for use in ELISA tests. 

These products are for research use only and not for use in diagnostic procedures.